242 related articles for article (PubMed ID: 2995573)
1. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
Dix RD; Mills J
J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
[TBL] [Abstract][Full Text] [Related]
2. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
Chan WL; Lukig ML; Liew FY
J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
[TBL] [Abstract][Full Text] [Related]
3. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
Dix RD; Pereira L; Baringer JR
Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
[TBL] [Abstract][Full Text] [Related]
5. Live vaccinia virus recombinants expressing herpes simplex virus genes.
Rooney JF; Wohlenberg CR; Moss B; Notkins AL
Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.
Ghiasi H; Nesburn AB; Wechsler SL
Vaccine; 1996 Feb; 14(2):107-12. PubMed ID: 8852405
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.
McKendall RR
Infect Immun; 1977 May; 16(2):717-9. PubMed ID: 193798
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
11. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
[TBL] [Abstract][Full Text] [Related]
14. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL
J Virol; 1994 Apr; 68(4):2118-26. PubMed ID: 8138996
[TBL] [Abstract][Full Text] [Related]
15. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.
Glorioso J; Schröder CH; Kumel G; Szczesiul M; Levine M
J Virol; 1984 Jun; 50(3):805-12. PubMed ID: 6328010
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation of experimental murine herpes simplex keratitis: II. Glycoprotein D protection.
Foster CS; Sandstrom IK; Wells PA; Thompson P; Daigle J; Opremcak EM
Curr Eye Res; 1988 Nov; 7(11):1051-61. PubMed ID: 2854037
[TBL] [Abstract][Full Text] [Related]
18. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.
Eisenberg RJ; Cerini CP; Heilman CJ; Joseph AD; Dietzschold B; Golub E; Long D; Ponce de Leon M; Cohen GH
J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
20. Protective immunization of mice with specific HSV-1 glycoproteins.
Chan WL
Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
